Advanced Linker Technology for Antibody-Drug Conjugates

Lead Research Organisation: University of Cambridge
Department Name: Chemistry

Abstract

Antibody-drug conjugates (ADCs) are a promising class of biopharmaceuticals, that combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs came to the market, ADC technologies have emerged, such as antibody engineering. However, there remain gaps in the development of linker optimisation and novel conjugation strategies. This project will focus on new linker technologies that will help to promote conjugate homogeneity and overall ADC stability.

Publications

10 25 50
publication icon
Walsh SJ (2021) Site-selective modification strategies in antibody-drug conjugates. in Chemical Society reviews

Studentship Projects

Project Reference Relationship Related To Start End Student Name
BB/M011194/1 01/10/2015 30/09/2023
1942966 Studentship BB/M011194/1 01/10/2017 30/12/2021 Friederike Marie Dannheim